Adjuvant breast radiotherapy, endocrine therapy, or both after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study
Author:
Funder
Northern Alberta Breast Cancer Program
Cross Cancer Institute
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,Hematology
Reference29 articles.
1. Breast cancer statistics, 2017, racial disparity in mortality by state;DeSantis;CA Cancer J Clin,2017
2. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial;Blamey;Eur J Cancer,2013
3. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343;Hughes;J Clin Oncol,2013
4. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial;Kunkler;Lancet Oncol,2015
5. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology;Gradishar;J Natl Compr Canc Netw,2016
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and safety of adjuvant therapies in older patients with breast cancer: a systematic review and meta-analysis of real-world data;Breast Cancer;2024-08-01
2. Whole Breast Irradiation in Comparison to Endocrine Therapy in Early Stage Breast Cancer—A Direct and Network Meta-Analysis of Published Randomized Trials;Cancers;2023-08-30
3. Adjuvant Therapy for Elderly Breast Cancer Patients after Breast-Conserving Surgery: Outcomes in Real World Practice;Cancers;2023-04-17
4. Avoiding Overtreatment of Women ≥70 With Early-Stage Breast Cancer: A Provider-Level Deimplementation Strategy;Journal of Surgical Research;2023-04
5. Effects of MAPK pathway inhibitors (AZD6244) on resistance of breast cancer cells to chemotherapy and targeted therapy;Materials Express;2023-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3